By Nigam Arora & Dr. Natasha Arora For the first time in two decades, the FDA has approved a new Alzheimer’s drug. The drug is from Biogen (BIIB). There is a great unmet need for Alzheimer’s treatment. Can you imagine investors getting richer by correctly buying the stocks of companies
Alzheimer’s Alzheimer’s is a terrible disease. A new patient is diagnosed with Alzheimer’s in the United States every 65 seconds. More than 5.8 million Americans are living with Alzheimer’s. For those who are over 65, one in 10 has Alzheimer’s dementia. There is no cure. Now a new treatment is
Prudent investors ought to pay attention to a menacing pattern developing in the stock market. Please click here for an annotated chart. The chart is of the Nasdaq 100 ETF QQQ, A similar pattern can be seen in S&P 500 ETF SPY, I picked QQQ because the pattern is more
Acorda Therapeutics (ACOR) rumor spreaders are out in force. They are misleading the uninformed investors about a statement Biogen (BIIB) just made at a conference. We have taken partial profits on Acorda at $30.20. Our highest short tranche in Acorda is from $33.48. The rumor related to Biogen buying Acorda